Summit Dermatology Partners, LLC – Trademark Portfolio
Entity Type: 16
Summit Dermatology Partners, LLC holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 4 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include OD. The owner is based in San Francisco, CA.
c/o Alpine Investors
One California Street, Suite 2900
San Francisco, CA 94111
Showing of trademarks Trademarks
Trademark Classifications
Summit Dermatology Partners, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Summit Dermatology Partners, LLC have?
Summit Dermatology Partners, LLC has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 abandoned, 1 cancelled.
What trademark classes does Summit Dermatology Partners, LLC file in?
Summit Dermatology Partners, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 35 (Advertising & Business). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are Summit Dermatology Partners, LLC's most well-known trademarks?
Summit Dermatology Partners, LLC's registered trademark portfolio includes well-known marks such as OD. These are among 1 currently registered trademark in the portfolio.
What is Summit Dermatology Partners, LLC's trademark registration success rate?
Summit Dermatology Partners, LLC has a 20% trademark registration rate, with 1 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.